ReviewFrontiers in endocrinology2014
Clinical perspectives and fundamental aspects of local cardiovascular and renal Renin-Angiotensin systems.
Review in Frontiers in endocrinology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 49 citations in OpenAlex.
- Sildenafil improves heart rate variability in dogs with asymptomatic myxomatous mitral valve degeneration.The Journal of veterinary medical science · 2017Trial
- Cardiac fibrosis: mechanistic insights and translational advances.Molecular biomedicine · 2026Review
- Long-term exposure to high-altitude hypoxic environments reduces blood pressure by inhibiting the renin-angiotensin system in rats.Frontiers in physiology · 2025Article
- Collecting Duct Pro(Renin) Receptor Contributes to Unilateral Ureteral Obstruction-Induced Kidney Injury via Activation of the Intrarenal RAS.Hypertension (Dallas, Tex. : 1979) · 2024Article
- Mechanism Underlying Triple VEGFR Inhibitor Tivozanib-Induced Hypertension in Mice Model.Pharmaceuticals (Basel, Switzerland) · 2023Article
- Pathophysiology and genetics of salt-sensitive hypertension.Frontiers in physiology · 2022Review
- Mechanisms of COVID-19-induced kidney injury and current pharmacotherapies.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2022Review
- Article
- Review
- RAAS, ACE2 and COVID-19; a mechanistic review.Saudi journal of biological sciences · 2021Review
- Effect of angiotensin receptor blockers and angiotensin-converting enzyme 2 on plasma equilibrium angiotensin peptide concentrations in cats with heart disease.Journal of veterinary internal medicine · 2021Article
- Role of the Renin-Angiotensin-Aldosterone System in Dystrophin-Deficient Cardiomyopathy.International journal of molecular sciences · 2020Review
- Inhibition of urea transporter ameliorates uremic cardiomyopathy in chronic kidney disease.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2020Article
- Mitochondrial angiotensin receptors and cardioprotective pathways.American journal of physiology. Heart and circulatory physiology · 2019Review
- The renin-angiotensin-aldosterone system and its suppression.Journal of veterinary internal medicine · 2019Review
- Inhibition of IL-1β by Aliskiren Improved Renal AQP2 Expression and Urinary Concentration Defect in Ureteral Obstruction and Release.Frontiers in physiology · 2019Article
- Alteration in the expression of the renin-angiotensin system in the myocardium of mice conceived by in vitro fertilization.Biology of reproduction · 2018Article
- Angiotensin II Signal Transduction: An Update on Mechanisms of Physiology and Pathophysiology.Physiological reviews · 2018Review
- Biotechnological production of the angiotensin-converting enzyme inhibitory dipeptide isoleucine-tryptophan.Engineering in life sciences · 2018Article
- Is angiotensin-(3-4) (Val-Tyr), the shortest angiotensin II-derived peptide, opening new vistas on the renin-angiotensin system?Journal of the renin-angiotensin-aldosterone system : JRAAS · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Evidence for the potential role of organ specific cardiovascular renin-angiotensin systems (RAS) has been demonstrated experimentally and clinically with respect to certain cardiovascular and renal diseases. These findings have been supported by studies involving pharmacological inhibition during ischemic heart disease, myocardial infarction, cardiac failure; hypertension associated with left ventricular ischemia, myocardial fibrosis and left ventricular hypertrophy; structural and functional changes of the target organs associated with prolonged dietary salt excess; and intrarenal vascular disease associated with end-stage renal disease. Moreover, the severe structural and functional changes induced by these pathological conditions can be prevented and reversed by agents producing RAS inhibition (even when not necessarily coincident with alterations in arterial pressure). In this review, we discuss specific fundamental and clinical aspects and mechanisms related to the activation or inhibition of local RAS and their implications for cardiovascular and renal diseases. Fundamental aspects involving the role of angiotensins on cardiac and renal functions including the expression of RAS components in the heart and kidney and the controversial role of angiotensin-converting enzyme 2 on angiotensin peptide metabolism in humans, were discussed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.